We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Scientists in Mali are studying a vaccine discovered in India that they say could halve the number of deaths caused by meningitis in West Africa once research is finished in 2009, reports the U.N. Integrated Regional Information Networks (IRIN).
Health Canada has announced that new information submitted by
Bristol-Myers Squibb on the antiviral drug Baraclude suggests the drug may be linked to the development of a treatment-resistant strain of HIV.
The European Union (EU)is still at least two years away from being prepared for an influenza pandemic, according to areport prepared by the European Centre for Disease Prevention and Control (ECDC) and published today.
India's Pharmaceutical Export Promotion Council (PHARMEXCIL) signed a memorandum of understanding (MOU) with the U.S. Pharmacopeia (USP) during a scientific meeting in Mumbai, India, last week.
Aurobindo Pharma has received another marketing authorization approval from the South African Medicines Control Council (MCC), this time for generic lisinopril tablets in 5-, 10- and 20-mg strengths.
The government of Canada and the Bill & Melinda Gates Foundation have announced new funding to support the Canadian HIV Vaccine Initiative in an effort to accelerate the development of effective vaccines and address critical research gaps identified by the Global HIV Vaccine Enterprise.
GlaxoSmithKline (GSK) has acquired exclusive rights to weight-loss drug orlistat for OTC use in markets outside the U.S., excluding Japan, and said it plans to file for approval in Europe by the end of the year.
Bentley Pharmaceuticals announced it has received approval from the Drugs Controller General of India to proceed with a Phase II clinical trial of Nasulin in Type 2 diabetes.
Israeli drugmaker Teva Pharmaceutical Industries' U.S. subsidiary has announced its support of proposed legislation that would prohibit brand manufacturers from paying generic companies to delay launching generic versions of their drugs, a practice called reverse payments.
A pathway for creating and marketing generic biologics could help health plan sponsors and patients save $71 billion over the next 10 years, according to an Express Scripts report.